logo
Plus   Neg
Share
Email

XFOR Prices Offering At $12/Shr

X4 Pharmaceuticals, Inc. (XFOR) plans to sell 3.66 million shares of its common stock at $12 per share. The gross proceeds from the offering are expected to be approximately $65.0 million. The offering is slated to close on or about November 29, 2019.

Cowen and Stifel are acting as joint book-running managers for this offering.

Canaccord Genuity and Oppenheimer & Co. are acting as lead managers, and H.C. Wainwright & Co. and Roth Capital Partners are acting as managers for the offering.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.

The lead drug candidate is Mavorixafor.

A pivotal Phase 3 clinical trial of Mavorixafor for the treatment of WHIM syndrome is underway. The 52-week trial is designed to enroll 18 to 28 subjects in
approximately 20 countries, followed by an open-label extension trial.

Mavorixafor is also being explored in other indications like Severe Congenital Neutropenia and advanced clear cell renal cell carcinoma. The Company is also in preparations to begin Phase 1b clinical trial of Mavorixafor in Waldenström's macroglobulinemia later this quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020. Shares of Deutsche Lufthansa AG were losing around 3 percent in German trading after the airline reported Thursday a loss in its second quarter, compared to prior year's profit with sharply lower revenues with collapse in demand for air travel due to the Corona pandemic. Going ahead, the airline projects a clearly negative adjusted EBIT in the second half of 2020 and a further significant decline
Follow RTT